1. IPSS Poor-Risk Karyotype as a Predictor of Outcome for Patients with Myelodysplastic Syndrome following Myeloablative Stem Cell Transplantation 
Thomas J. Nevill, John D. Shepherd, Heather J. Sutherland, Yasser R. Abou Mourad, Julye C. Lavoie, Michael J. Barnett, Stephen H. Nantel, Cynthia L. Toze, Donna E. Hogge, Donna L. Forrest, Kevin W. Song, Maryse M. Power, Janet Y. Nitta, Yunfeng Dai, Clayton A. Smith 
Biology of Blood and Marrow Transplantation 
Volume 15, Issue 2, Pages (February 2009)
DOI: /j.bbmt
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
EFS following allogeneic BM (n = 114) and blood (PB, n = 42) SCT for patients with MDS/sAML.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
NRM following allogeneic BM (n = 114) and blood (PB, n = 42) SCT for patients with MDS/sAML.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
(A) EFS and (B) probability of relapse following allogeneic SCT for MDS/sAML according to FAB diagnosis.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
(A) EFS and (B) NRM according to year of allogeneic SCT for patients with MDS/sAML.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
EFS following allogeneic BM and blood (PB) SCT for MDS/sAML and (A) good- or intermediate-risk karytoype and (B) poor-risk karyotype.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions